INC.

Invivoscribe s’associe à Complete Genomics pour développer et commercialiser des tests de biomarqueurs pour l’oncologie et la recherche sur le cancer USA – Français USA – English India – English Latin America – español USA – español Brazil – Português USA – Deutsch

by

SAN DIEGO et SAN JOSÉ, Californie, 3 juin 2023 /PRNewswire/ — Invivoscribe et Complete Genomics ont annoncé aujourd’hui avoir conclu un partenariat pour développer et commercialiser des tests de biomarqueurs sur les plateformes NGS de Complete Genomics. Le territoire est mondial et les domaines sont l’oncologie et la recherche sur le cancer. Selon les termes de l’accord, Invivoscribe … Read more

At ASCO ’23, AI Precision Oncology Company Perthera Unveils Premium Experience for Clinicians with New Options for Ordering and Access to Enhanced Perthera Analytics

by

CHICAGO, June 2, 2023 /PRNewswire/ — ASCO 2023 – McCormick Place, In advance of a new Current Procedural Terminology (CPT) Category III code that will go into effect on July 1st, Perthera, the leader in AI precision oncology solutions, introduced its latest generation of clinical support tools, including Perthera Lab Direct and Perthera RWE Navigator. … Read more

EpicentRx Presents Updates on its Oncology Clinical Development Programs at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

by

Company details follow-on Phase 2b study design in head and neck cancer for its lead small molecule candidate, RRx-001 Company also presented positive first-in-human data from its TGF-β trap vector, AdAPT-001 TORREY PINES, Calif., June 2, 2023 /PRNewswire/ — EpicentRx, Inc. (“EpicentRx”), a leading-edge, clinical-stage biopharmaceutical company, today presented clinical progress updates for two lead … Read more

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

by

WALTHAM, Mass., June 2, 2023 /PRNewswire/ — Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on June 1, 2023 the Company granted inducement awards to purchase up to 397,900 shares of common stock to eighteen new employees under the Company’s 2023 Inducement Plan. The stock … Read more

NRx Pharmaceuticals to Host Corporate and Strategic Update Conference Call on Monday, June 5, 2023

by

RADNOR, Pa., June 2, 2023 /PRNewswire/ — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced it will host a corporate and strategic update conference call on Monday, June 5, 2023 at 8:30 a.m. EDT. A live webcast of the conference call will be available on the Company’s website … Read more

CNO Financial Group Announces New Carmel-based Location for Corporate Headquarters

by

The company inks a deal to move to 11299 Illinois St. CARMEL, Ind., June 2, 2023 /PRNewswire/ — CNO Financial Group (NYSE: CNO) announced today that it will relocate its corporate headquarters to 11299 Illinois Street in Carmel, Indiana, from its current location at 11825 N. Pennsylvania Street in Carmel, Indiana. The move will take place … Read more

TOTALMED INC. NAMES JUSTIN TOMLIN CHIEF STRATEGY OFFICER

by

APPLETON, Wis., June 2, 2023 /PRNewswire/ — TotalMed Inc. announced that the company has appointed Justin Tomlin as its first Chief Strategy Officer to join the company’s executive leadership team. In his new role, Tomlin is responsible for enterprise strategy, workforce technology solutions and customer innovation & experience. TOTALMED INC. NAMES JUSTIN TOMLIN CHIEF STRATEGY OFFICER … Read more

Dragonfly Therapeutics presentará los resultados de fase 1 de la monoterapia con DF1001

by

-Dragonfly Therapeutics presentará los resultados de fase 1 de la monoterapia con DF1001 en la reunión anual ASCO 2023 Una presentación oral titulada “Estudio de fase 1/2 de DF1001, un TriNKET® inmunomodulador dirigido contra HER2, en pacientes con tumores sólidos avanzados: Fase 1 DF1001 Resultados del escalado de dosis en monoterapia” será ofrecida por Howard … Read more

$1.55M Raised for Plan A™ Male Birth Control Product, Seeking Clinical Trials in 2023

by

LOS ANGELES, June 2, 2023 /PRNewswire/ — After years in development by the Parsemus Foundation, NEXT Life Sciences, Inc. has announced its plans to bring a new contraceptive product to market through Plan A™ – a safe, effective, reversible birth control for men. “In developing Plan A™, NEXT has seen increasing demand for male contraception … Read more

Le Dr Robin Edwards et le Dr David Ferry rejoignent l’équipe de direction clinique de Dragonfly pour aider à gérer son pipeline clinique en pleine croissance USA – Français USA – Deutsch USA – español USA – English USA – English

by

Six médicaments développés par Dragonfly sont actuellement en clinique. WALTHAM, Massachusetts, 2 juin 2023 /PRNewswire/ — Dragonfly Therapeutics, Inc., a annoncé aujourd’hui avoir élargi son équipe de direction clinique en y intégrant le Dr Robin Edwards, anciennement directeur mondial des sciences translationnelles chez Daiichi Sankyo et directeur des sciences translationnelles chez Bristol Myers Squibb, et … Read more